Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Polycystic Ovary Syndrome 5Insulin Resistance 3Diabetes Mellitus, Type 2 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Diabetes Mellitus 2Carotid Intimal Medial Thickness 1 2Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1Skin Neoplasms 1Prostatic Neoplasms 1Pharmacokinetics of MDV3100 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1Memory Disorders 1Liposarcoma, Myxoid 1Liposarcoma 1Leukoplakia, Oral 1Leukemia, Myeloid, Chronic-Phase 1Inflammation 1Head and Neck Neoplasms 1Glioblastoma 1Cognitive Dysfunction 1Carcinoma, Squamous Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

Surveys and Questionnaires 1Sugars 1Pioglitazone 1Methods 1Interviews as Topic 1Hematologic Tests 1Echocardiography 1Donepezil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Memory Disorders × Pioglitazone × Clear all
NCT01151670 2018-08-01

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Wake Forest University Health Sciences

Phase 1 Completed
18 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Memory Disorders, Meningioma, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡